Level of DNA topoisomerase IIα mRNA predicts the treatment response of relapsed acute leukemic patients

Yan Hua Wang; Minoko Takanashi; Kazue Tsuji; Norina Tanaka; Masayuki Shiseki; Naoki Mori; Toshiko Motoji

doi:10.1016/j.leukres.2008.12.012

Level of DNA topoisomerase IIα mRNA predicts the treatment response of relapsed acute leukemic patients

Yan Hua Wang, Minoko Takanashi, Kazue Tsuji, Norina Tanaka, Masayuki Shiseki, Naoki Mori, Toshiko Motoji^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

The DNA topoisomerase IIα (Topo IIα) is known as a target enzyme for many chemotherapeutic agents. We investigated the Topo IIα mRNA expression by real-time RT-PCR in 37 paired samples at diagnosis and at relapse of acute leukemic patients in relation to drug sensitivity and clinical outcome. The Topo IIα levels in leukemic blasts at relapse were significantly higher than that at diagnosis, especially in ALL. The increase in the Topo IIα level at relapse was significant in cases which could not achieve a second remission, but not significant in cases which achieved a second remission. These results suggest that the change of Topo IIα expression in leukemic blasts at relapse may predict therapeutic responsiveness.

Original language	English
Pages (from-to)	902-907
Number of pages	6
Journal	Leukemia Research
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2008.12.012
Publication status	Published - Jul 2009
Externally published	Yes

Keywords

Acute leukemia
DNA topoisomerase IIα (Topo IIα)
Drug sensitivity
Multidrug resistance (MDR)
Real-time RT-PCR

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2008.12.012

Cite this

@article{e6c74d30c79f4527b62af64040492f25,

title = "Level of DNA topoisomerase IIα mRNA predicts the treatment response of relapsed acute leukemic patients",

abstract = "The DNA topoisomerase IIα (Topo IIα) is known as a target enzyme for many chemotherapeutic agents. We investigated the Topo IIα mRNA expression by real-time RT-PCR in 37 paired samples at diagnosis and at relapse of acute leukemic patients in relation to drug sensitivity and clinical outcome. The Topo IIα levels in leukemic blasts at relapse were significantly higher than that at diagnosis, especially in ALL. The increase in the Topo IIα level at relapse was significant in cases which could not achieve a second remission, but not significant in cases which achieved a second remission. These results suggest that the change of Topo IIα expression in leukemic blasts at relapse may predict therapeutic responsiveness.",

keywords = "Acute leukemia, DNA topoisomerase IIα (Topo IIα), Drug sensitivity, Multidrug resistance (MDR), Real-time RT-PCR",

author = "Wang, {Yan Hua} and Minoko Takanashi and Kazue Tsuji and Norina Tanaka and Masayuki Shiseki and Naoki Mori and Toshiko Motoji",

year = "2009",

month = jul,

doi = "10.1016/j.leukres.2008.12.012",

language = "English",

volume = "33",

pages = "902--907",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "7",

}

TY - JOUR

T1 - Level of DNA topoisomerase IIα mRNA predicts the treatment response of relapsed acute leukemic patients

AU - Wang, Yan Hua

AU - Takanashi, Minoko

AU - Tsuji, Kazue

AU - Tanaka, Norina

AU - Shiseki, Masayuki

AU - Mori, Naoki

AU - Motoji, Toshiko

PY - 2009/7

Y1 - 2009/7

N2 - The DNA topoisomerase IIα (Topo IIα) is known as a target enzyme for many chemotherapeutic agents. We investigated the Topo IIα mRNA expression by real-time RT-PCR in 37 paired samples at diagnosis and at relapse of acute leukemic patients in relation to drug sensitivity and clinical outcome. The Topo IIα levels in leukemic blasts at relapse were significantly higher than that at diagnosis, especially in ALL. The increase in the Topo IIα level at relapse was significant in cases which could not achieve a second remission, but not significant in cases which achieved a second remission. These results suggest that the change of Topo IIα expression in leukemic blasts at relapse may predict therapeutic responsiveness.

AB - The DNA topoisomerase IIα (Topo IIα) is known as a target enzyme for many chemotherapeutic agents. We investigated the Topo IIα mRNA expression by real-time RT-PCR in 37 paired samples at diagnosis and at relapse of acute leukemic patients in relation to drug sensitivity and clinical outcome. The Topo IIα levels in leukemic blasts at relapse were significantly higher than that at diagnosis, especially in ALL. The increase in the Topo IIα level at relapse was significant in cases which could not achieve a second remission, but not significant in cases which achieved a second remission. These results suggest that the change of Topo IIα expression in leukemic blasts at relapse may predict therapeutic responsiveness.

KW - Acute leukemia

KW - DNA topoisomerase IIα (Topo IIα)

KW - Drug sensitivity

KW - Multidrug resistance (MDR)

KW - Real-time RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=67349162929&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.12.012

DO - 10.1016/j.leukres.2008.12.012

M3 - Article

C2 - 19185918

AN - SCOPUS:67349162929

SN - 0145-2126

VL - 33

SP - 902

EP - 907

JO - Leukemia Research

JF - Leukemia Research

IS - 7

ER -

Level of DNA topoisomerase IIα mRNA predicts the treatment response of relapsed acute leukemic patients

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this